Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Orellana Paucar, Adriana Monserrath ^a,b   Afrikanova, Tatiana ^a   Thomas, Joice ^c   Aibuldinov, Yelaman K ^c   Dehaen, Wim ^c   De Witte, Peter A M ^a   Esguerra, Camila V ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSIDAD DE CUENCA   (Ecuador)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AR TURMERONE; BRAIN DERIVED NEUROTROPHIC FACTOR; DIAZEPAM; ETIRACETAM; PROTEIN C FOS; SESQUITERPENOID; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BODY EQUILIBRIUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG SYNTHESIS; EMBRYO; GENE EXPRESSION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; ONCOGENE C FOS; SEIZURE; WALKING; ZEBRA FISH;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INJECTIONS, INTRAPERITONEAL; KETONES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PENTYLENETETRAZOLE; POSTURAL BALANCE; PROTO-ONCOGENE PROTEINS C-FOS; SEIZURES; SESQUITERPENES; ZEBRAFISH;

EID: 84892668173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081634     Document Type: Article

References (84)

1. World Health Organization (2005) Atlas: epilepsy care in the world. Geneva: WHO Press. 91 pp.
2. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR (2010) Estimation of the burden of active and life-time epilepsy: a metaanalytic approach. Epilepsia 51[5]: 883-890. doi:10.1111/j.1528-1167.2009.02481.x. PubMed: 20067507.
3. Fejerman N (2012) Genetic etiologies associated with severe epilepsies in infancy. Arch Argent Pediatría 110[5]: 421-429. doi:10.5546/aap.2012. 421.
4. Alam S, Lux AL (2012) Epilepsies in infancy. Arch Dis Child 97[11]: 985-992. doi:10.1136/archdischild-2011-301119. PubMed: 22962318.
5. Scher MS (2006) Neonatal seizure classification: a fetal perspective concerning childhood epilepsy. Epilepsy Res 70, Supplement: 41-57. doi:10.1016/j.eplepsyres.2006.03.002. PubMed: 16624524.
6. Alarcón G, Valentín A (2012) Introduction to epilepsy. New York: Cambridge University Press. 624 pp.
7. Reid CA, Berkovic SF, Petrou S (2009) Mechanisms of human inherited epilepsies. Prog Neurobiol 87[1]: 41-57. doi:10.1016/j.pneurobio.2008.09.016. PubMed: 18952142.
8. Dobrin S (2012) Seizures and epilepsy in adolescents and adults. Dis Mon 58[12]: 708-729. doi:10.1016/j.disamonth.2012.08.011. PubMed: 23149523.
9. Schmidt D (2009) Drug treatment of epilepsy: options and limitations. Epilepsy Behav 15[1]: 56-65. doi:10.1016/j.yebeh.2009.02.030. PubMed: 19236951.
10. Cramer JA, Mintzer S, Wheless J, Mattson RH (2010) Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 10[6]: 885-891. doi:10.1586/ern.10.71. PubMed: 20518605.
11. Abou-Khalil B, Schmidt D (2012) Antiepileptic drugs: advantages and disadvantages. Handb. Clin Neurol 108: 723-739.
12. Park S-P, Kwon S-H (2008) Cognitive Effects of Antiepileptic Drugs. J Clin Neurol 4[3]: 99-106. doi:10.3988/jcn.2008.4.3.99. PubMed: 19513311.
13. Das N, Dhanawat M, Shrivastava SK (2012) An overview on antiepileptic drugs. Drug Discov Ther 6[4]: 178-193. PubMed: 23006988.
14. Doǧan S, Ozberk S, Yurci A (2011) Pregabalin-induced hepatotoxicity. Eur J Gastroenterol Hepatol 23[7]: 628. doi:10.1097/MEG. 0b013e328346df7a. PubMed: 21654262.
15. Bota RG, Ligasan AP, Najdowski TG, Novac A (2011) Acute hypersensitivity syndrome caused by valproic acid: a review of the literature and a case report. Perm J 15[2]:80-84.
16. Gao L, Xia L, Zhao F-L, Li S-C (2013) Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res 103[1]: 31-44. doi:10.1016/j.eplepsyres.2012.06.005. PubMed: 22776828.
17. Schachter SC (2009) Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics 6[2]: 415-420. doi:10.1016/j.nurt.2008.12. 004. PubMed: 19332338.
18. Abdullah JM (2011) Interesting Asian plants: their compounds and effects on electrophysiology and behaviour. Malays J Med Sci 18[4]: 1-4. PubMed: 22589667.
19. Hosseini M, Ghasemzadeh Rahbardar M, Sadeghnia HR, Rakhshandeh H (2011) Effects of different extracts of Rosa damascena on pentylenetetrazol-induced seizures in mice. J Chin Integr Med 9[10]: 1118-1124. doi:10.3736/jcim20111013. PubMed: 22015194.
20. Marchetti C, Gavazzo P, Stafford GI, Van Staden J (2011) South African plants used in traditional medicine to treat epilepsy have an antagonistic effect on NMDA receptor currents. J Ethnopharmacol 137[1]: 382-388. doi:10.1016/j.jep.2011.05.038. PubMed: 21669274.
21. Orellana-Paucar AM, Serruys A-SK, Afrikanova T, Maes J, De Borggraeve W et al. (2012) Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models. Epilepsy Behav 24[1]: 14-22. doi:10.1016/j.yebeh.2012.02.020. PubMed: 22483646.
22. Prasad S, Aggarwal B (2011) Turmeric, the golden spice: from traditional medicine to modern medicine. In: IFF BenzieS Wachtel- Galor. Herb Med Biomol Clin Asp. 2nd ed. Boca Raton, FL: CRC Press. p. 13.
23. Du P, Tang H-Y, Li X, Lin H-J, Peng W-F et al. (2012) Anticonvulsive and antioxidant effects of curcumin on pilocarpine-induced seizures in rats. Chin Med J 125[11]: 1975-1979. PubMed: 22884064.
24. Sumanont Y, Murakami Y, Tohda M, Vajragupta O, Watanabe H et al. (2006) Prevention of kainic acid-induced changes in nitric oxide level and neuronal cell damage in the rat hippocampus by manganese complexes of curcumin and diacetylcurcumin. Life Sci 78[16]: 1884-1891. doi:10.1016/j.lfs.2005.08.028. PubMed: 16266725.
25. Noor NA, Aboul Ezz HS, Faraag AR, Khadrawy YA (2012) Evaluation of the antiepileptic effect of curcumin and Nigella sativa oil in the pilocarpine model of epilepsy in comparison with valproate. Epilepsy Behav 24[2]: 199-206. doi:10.1016/j.yebeh.2012.03.026. PubMed: 22575751.
26. Antony B, Merina B, Iyer VS, Judy N, Lennertz K et al. (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95®CG (Biocurcumax[TM]), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70[4]: 445-449. doi:10.4103/0250-474X.44591. PubMed: 20046768.
27. Prakash P, Misra A, Surin WR, Jain M, Bhatta RS et al. (2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 127[2]: 111-118. doi:10.1016/j.thromres.2010.11.007. PubMed: 21144557.
28. Yong-Xue S, Yongjin L, Dongping Z, Gang W, Zhichang L et al. (2012) Pharmacokinetic study of rhizoma Curcumae Oil and rhizoma Curcumae oil-β-cyclodextrin inclusion complex in pigs after oral administration. J Vet Pharmacol Ther 35[1]: 47-51. PubMed: 21470245.
29. Löscher W, Schmidt D (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52[4]: 657-678. doi:10.1111/j.1528-1167.2011.03024.x. PubMed: 21426333.
30. Mandhane SN, Aavula K, Rajamannar T (2007) Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 16[7]: 636-644. doi:10.1016/j.seizure. 2007.05.005. PubMed: 17570689.
31. Löscher W, Hönack D, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8[3]: 171-189. doi: 10.1016/0920-1211(91)90062-K. PubMed: 1907909.
32. Löscher W (2009) Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 610[1-3]: 1-11. doi:10.1016/j.ejphar.2009.03.025. PubMed: 19292981.
33. Barton ME, Klein BD, Wolf HH, White HS (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47[3]: 217-227. doi:10.1016/S0920-1211(01)00302-3. PubMed: 11738929.
34. Carter RJ, Morton J, Dunnett SB (2001) Motor coordination and balance in rodents. Curr Protoc Neurosci 15: 8.12.1-8.12.14. PubMed: 18428540.
35. Luong TN, Carlisle HJ, Southwell A, Patterson PH (2011) Assessment of motor balance and coordination in mice using the balance beam. J Vis Exp 49: 2376. PubMed: 21445033.
36. Brooks SP, Trueman RC, Dunnett SB (2011) Assessment of motor coordination and balance in mice using the rotarod, elevated bridge, and footprint tests. Curr Protoc Mouse Biol 2: 37-53.
37. Baraban SC, Taylor MR, Castro PA, Baier H (2005) Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 131[3]: 759-768. doi:10.1016/ j.neuroscience.2004.11.031. PubMed: 15730879.
38. Schreiber SS, Tocco G, Shors TJ, Thompson RF (1991) Activation of immediate early genes after acute stress. Neuroreport 2[1]: 17-20. doi: 10.1097/00001756-199101000-00004. PubMed: 1768844.
39. Baxendale S, Holdsworth CJ, Santoscoy PLM, Harrison MRM, Fox J et al. (2012) Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures. Dis Model Mech 5[6]: 773-784.
40. Szyndler J, Maciejak P, Turzyńska D, Sobolewska A, Taracha E et al. (2009) Mapping of c-Fos expression in the rat brain during the evolution of pentylenetetrazol-kindled seizures. Epilepsy Behav 16[2]: 216-224. doi:10.1016/j.yebeh.2009.07.030. PubMed: 19713157.
41. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9[4]: 519-525. doi: 10.1038/nn1659. PubMed: 16501568.
42. Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S (2010) Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70[5]: 271-288. PubMed: 20186709.
43. McNamara JO, Scharfman HE (2010) Temporal Lobe Epilepsy and the BDNF Receptor, TrkB. Epilepsia 51: 46. doi:10.1111/j.1528-1167.2010.02832.x.
44. Brown WC, Schiffman DO, Swinyard EA, Goodman LS (1953) Comparative assay of antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 107[3]: 273-283. PubMed: 13035666.
45. Hartman AL, Lyle M, Rogawski MA, Gasior M (2008) Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 49[2]: 334-339. doi:10.1111/j.1528-1167.2007.01430.x. PubMed: 18070095.
46. Giardina WJ, Gasior M (2009) Acute seizure tests in epilepsy research: electroshock- and chemical-induced convulsions in the mouse. Curr Protoc. Pharmacol 45: 5.22.1-5.22.37.
47. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H et al. (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5[1]: 71-78. doi: 10.1385/NCC:5:1:71. PubMed: 16960300.
48. Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR et al. (2005) The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol 19[3]: 221-227. doi: 10.1177/0269881105051524. PubMed: 15888506.
49. Guo J, Duan JA, Shang EX, Tang Y, Qian D (2009) Determination of ligustilide in rat brain after nasal administration of essential oil from Rhizoma Chuanxiong. Fitoterapia 80[3]: 168-172. doi:10.1016/j.fitote.2009.01. 003. PubMed: 19535021.
50. Christie WW (1993) Preparation of lipid extracts from tissues. Adv Lipid Methodol 2: 195-213.
51. Mehrotra N, Sabarinath S, Suryawanshi S, Raj K, Gupta RC LC-UV assay for simultaneous estimation of aromatic turmerone, α/β-turmerone and curlone: major bisabolane sesquiterpenes of turmeric oil in rabbit plasma for application to pharmacokinetic studies. Chromatographia 69[9-10]: 1077-1082. doi:10.1365/s10337-009-1007-1.
52. Rupe H, Wiederkehr F (1924) Die Konstitution des Curcumons aus dem Curcuma-öl. Helv Chim Acta 7[1]: 654-669. doi:10.1002/hlca.19240070181.
53. Rupe H, Clar G, St. Pfau A, Plattner P (1934) Zur Kenntnis der flüchtigen Pflanzenstoffe II. Über Turmeron, den Riechstoff des Curcumaöls. Helv Chim Acta 17[1]:372-389.
54. Stables JP, Kupferberg HJ (1997) The NIH Anticonvulsant Drug Development [ADD] Program: preclinical anticonvulsant screening project. In: G AvanziniP TanganelliM Avoli. Mol Cell Targets Anti-Epileptic Drugs. London: John Libbey. pp. 191-198.
55. Li S, Yuan W, Deng G, Wang P, Yang P, et al. (2011) Chemical composition and product quality control of turmeric (Curcuma longa L.]. Pharm Crops 2:28.
56. Rupe H, Luksch E, Steinbach A (1909) Über Curcuma-Öl. Berichte Dtsch Chem Ges 42[2]: 2515-2520. doi:10.1002/cber.190904202156.
57. Barton ME, Peters SC, Shannon HE (2003) Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 56[1]: 17-26. doi:10.1016/j.eplepsyres. 2003.08.001. PubMed: 14529950.
58. Wojda E, Wlaz A, Patsalos PN, Luszczki JJ (2009) Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res 86[2-3]: 163-174. doi:10.1016/j.eplepsyres.2009.06.003. PubMed: 19596559.
59. Surges R, Volynski KE, Walker MC (2008) Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 1[1]: 13-24. doi:10.1177/1756285608094212. PubMed: 21180561.
60. Klitgaard H, Matagne A, Gobert J, Wülfert E (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353[2-3]: 191-206. doi:10.1016/S0014-2999(98)00410-5. PubMed: 9726649.
61. Duncan GE, Kohn H (2005) The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 67[1-2]: 81-87.PubMed: 16214306.
62. Rocamora R, Wagner K, Schulze-Bonhage A (2006) Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 15[6]: 428-433. doi: 10.1016/j.seizure.2006.05. 012. PubMed: 16837220.
63. Eggers C, Burghaus L, Fink GR, Dohmen C (2009) Epilepsia partialis continua responsive to intravenous levetiracetam. Seizure J Br Epilepsy Assoc 18[10]:716-718.
64. Cilio MR, Bianchi R, Balestri M, Onofri A, Giovannini S et al. (2009) Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. Epilepsy Res 86[1]: 66-71. doi:10.1016/j.eplepsyres.2009.05.004. PubMed: 19520548.
65. Piña-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J et al. (2009) Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 50[5]: 1141-1149. doi: 10.1111/j.1528-1167.2008.01981.x. PubMed: 19243423.
66. Gambardella A, Labate A, Colosimo E, Ambrosio R, Quattrone A (2008) Monotherapy for partial epilepsy: focus on levetiracetam. Neuropsychiatr Dis Treat 4[1]: 33-38. PubMed: 18728811.
67. Malizia AL, Gunn RN, Wilson SJ, Waters SH, Bloomfield PM et al. (1996) Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. Neuropharmacology 35[9-10]: 1483-1491. doi:10.1016/S0028-3908(96)00072-X. PubMed: 9014164.
68. Liju VB, Jeena K, Kuttan R (2012) Acute and subchronic toxicity as well as mutagenic evaluation of essential oil from turmeric [Curcuma longa L.). Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 53C:52-61.
69. Joshi J, Ghaisas S, Vaidya A, Vaidya R, Kamat DV et al. (2003) Early human safety study of turmeric oil (Curcuma longa oil) administered orally in healthy volunteers. J Assoc Physicians India 51: 1055-1060. PubMed: 15260388.
70. Ng T-P, Chiam P-C, Lee T, Chua H-C, Lim L et al. (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164[9]: 898-906. doi:10.1093/aje/kwj267. PubMed: 16870699.
71. Eigner D, Scholz D (1999) Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 67[1]: 1-6. doi:10.1016/S0378-8741(98)00234-7. PubMed: 10616954.
72. Villegas I, Sánchez-Fidalgo S, Alarcón de la Lastra C (2008) New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 52[9]: 1040-1061. doi:10.1002/mnfr.200700280. PubMed: 18655004.
73. Hutchins-Wolfbrand A, Mistry Anahita (2011) Dietary turmeric potentially reduces the risk of cancer. Asian Pacific J Cancer Prev 12: 3169-3173.
74. Olsen RW (1981) The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anti-convulsant drugs. Mol Cell Biochem 39: 261-279. doi:10.1007/BF00232579. PubMed: 6273709.
75. Meldrum B (2002) Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res 50[1-2]: 33-40. doi: 10.1016/S0920-1211(02)00066-9. PubMed: 12151115.
76. Lüscher BP, Baur R, Goeldner M, Sigel E (2012) Influence of GABA[A] receptor α subunit isoforms on the benzodiazepine binding site. PLOS ONE 7[7]: e42101. doi:10.1371/journal.pone.0042101. PubMed: 22848717.
77. Rambeck B, Jürgens UH, May TW, Pannek HW, Behne F et al. (2006) Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 47[4]: 681-694. doi:10.1111/j.1528-1167.2006.00504.x. PubMed: 16650134.
78. Mao X, Guo F, Yu J, Min D, Wang Z et al. (2010) Up-regulation of GABA transporters and GABA[A] receptor α1 subunit in tremor rat hippocampus. Neurosci Lett 486[3]: 150-155. doi:10.1016/j.neulet.2010.09.033. PubMed: 20851161.
79. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci 10[9]: 1089-1093. doi:10.1038/nn1971. PubMed: 17726474.
80. Godukhin OV, Levin SG, Parnyshkova EY (2009) The effects of interleukin-10 on the development of epileptiform activity in the hippocampus induced by transient hypoxia, bicuculline, and electrical kindling. Neurosci Behav Physiol 39[7]: 625-631. doi:10.1007/s11055-009-9187-6. PubMed: 19621265.
81. Poulsen FR, Jahnsen H, Blaabjerg M, Zimmer J (2002) Pilocarpine-induced seizure-like activity with increased BNDF and neuropeptide Y expression in organotypic hippocampal slice cultures. Brain Res 950[1-2]: 103-118. PubMed: 12231234.
82. Ballarín M, Ernfors P, Lindefors N, Persson H (1991) Hippocampal damage and kainic acid injection induce a rapid increase in mRNA for BDNF and NGF in the rat brain. Exp Neurol 114[1]: 35-43. doi: 10.1016/0014-4886(91)90082- N. PubMed: 1915733.
83. Ernfors P, Bengzon J, Kokaia Z, Persson H, Lindvall O (1991) Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. Neuron 7[1]: 165-176. doi: 10.1016/0896-6273(91)90084-D. PubMed: 1829904.
84. Teng HK, Teng KK, Lee R, Wright S, Tevar S et al. (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 25[22]: 5455-5463. doi:10.1523/JNEUROSCI.5123-04.2005. PubMed: 15930396.